Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7942)	9/19/2000 12:53:22 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

The Management of Cancer Pain Nathan I. Cherny, MBBS ca-journal.org Radiopharmaceuticals Radiolabeled agents that are absorbed into areas of high bone turnover have been evaluated as potential therapies for metastatic bone disease. Such an approach has the advantage of addressing all sites of involvement with relatively selective absorption, thus limiting radiation exposure to normal tissues. Excellent clinical responses with acceptable hematological toxicity have been observed with a range of radiopharmaceuticals. Systemically administered phosphorus-32 has long been known to be an effective agent in the management of metastatic bone pain, and recent studies have demonstrated efficacy without substantial myelosupression.194,195 The best studied and most commonly used radionuclide is strontium-89. Large, prospectively randomized clinical trials have demonstrated its efficacy as a first-line therapy196 or as an adjuvant to external-beam radiotherapy.197 This approach is contraindicated in patients who have a platelet count less than 60,000 or a white cell count less than 2.4,198 and is not advised for patients with very poor performance status.199 Using another approach, bone-seeking radiopharmaceuticals, which link a radioisotope with a bisphosphonate compound, have been synthesized. Positive experience has been reported with samarium-153-ethylenediaminetetramethylene phosphonic acid,200 and rhenium-186-hydroxyethylidene diphosphonate.201 200. Resche I, Chatal JF, Pecking A, et al: A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-1591. From Cyto web site: According to American Cancer Society and National Cancer Institute statistics, approximately 600,000 new cases of cancer that typically metastasize to bone occurred in the United States in 1997. We believe that over 200,000 patients each year will suffer from bone pain that is severe enough to require intervention. Based on this information, we believe that the market for Quadramet is $80 million in the United States based on 20% of this patient population. Quadramet has many characteristics which we believe are advantageous for the treatment of cancer bone pain, including early onset of pain relief, lasting up to four months with a single injection; predictability of recovery from bone marrow toxicity; ease of administration and length of pain relief. In addition, due to its pharmacokinetic properties, the radioactive plasma half-life is only five to six hours Jim